Cited by 123Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeuroscience and Neuropharmacology Research

The Many Faces of Astrocytes in Alzheimer's Disease

Open access
Monterey, Michael D., Wei, Haichao, Wu, Xizi, Wu, Jia Qian·2021·Frontiers in Neurology

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease and is the most common cause of dementia in an aging population. The majority of research effort has focused on the role of neurons in neurodegeneration and current therapies have limited ability to slow disease progression. Recently more attention has been given to the role of astrocytes in the process of neurodegeneration. Specifically, reactive astrocytes have both advantageous and adverse effects during neurodegeneration. The ability to isolate and depict astrocyte phenotype has been challenging. However, with the recent development of single-cell sequencing technologies researchers are provided with the resource to delineate specific biomarkers associated with reactive astrocytes in AD. In this review, we will focus on the role of astrocytes in normal conditions and the pathological development of AD. We will further review recent developments in the understanding of astrocyte heterogeneity and associated biomarkers. A better understanding of astrocyte contributions and phenotypic changes in AD can ultimately lead to more effective therapeutic targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2021.619626

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Glial cells are the primary cells involved in neuroinflammation and neurodegeneration.

    “As we have discussed above, glial cells are the primary cells involved in neuroinflammation and neurodegeneration. Their crucial function in the development and progression of neurodegenerative diseases has also been elaborated in many reviews in the past year.275,468,469”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [468]

    In “Astrocytes in Alzheimer’s Disease” (page unavailable), the review calls microglia the primary inflammatory cells of the CNS and describes astrocyte involvement in neuroinflammation and Alzheimer’s pathology. It does not establish that glial cells as a whole are the primary cells involved in neurodegeneration across diseases. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

1 of the 127 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Monterey, M. D., Wei, H., Wu, X., & Wu, J. Q.
Affiliations
  • The University of Texas Health Science Center at Houston (US)
  • Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Wu, Jia Qian
Venue
Frontiers in Neurology
Published
2021-08-31
Volume
12
Pages
619626-619626
ISSN
1664-2295 (ISSN-L)
OpenAlex
W3197066362
Cited by
117
References
127
Citations by year
2026: 12 · 2025: 27 · 2024: 34 · 2023: 29 · 2022: 15
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Eye Institute (R21EY028647)
  • National Institute of Neurological Disorders and Stroke (R21NS113068, R01NS088353)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
Alzheimer's disease, astrocytes, reactive astrocytes, astrocyte heterogeneity, neurodegeneration, single-cell sequencing, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review